Neoadjuvant Anti-PD-1 Antibody (Toripalimab) or Combined With Chemotherapy in HNSCC Patients
Status:
Unknown status
Trial end date:
2021-11-07
Target enrollment:
Participant gender:
Summary
This study evaluate either Toripalimab or combined with chemotherapy as neoadjuvant treatment
for patients with head and neck squamous cell carcinoma. Participants in arm A receive
Toripalimab, in arm B receive Toripalimab plus PC (paclitaxel and carboplatin), arm C with
Toripalimab plus modified TPF(paclitaxel and cisplatin and 5-fu).